Medical/Pharmaceuticals
QDX Congratulates Co-Founder and Head of Research A/Prof. Giuseppe Barca on Receiving the 2025 Dirac Medal
SINGAPORE, May 8, 2025 /PRNewswire/ -- QDX proudly congratulates its Co-Founder and Head of Research,A/Prof. Giuseppe Barca, on being awarded the 2025 Dirac Medal, the highest international honour for early-career researchers in theoretical and computational chemistry. Presented by the World Ass...
2025-05-08 16:10
2478
Penetrium™ Breaks Oncology Barriers: The Solution to Cold Tumors and Metastatic Cancer Unveiled at AACR 2025
* Penetrium™ Achieves Historic Breakthrough * Overcoming Cold Tumor Failure and the Challenge of Metastatic Cancer in Immunotherapy and Antibody Therapy * Presented at AACR 2025, Chicago CHICAGO, May 7, 2025 /PRNewswire/ -- Hyundai Bioscience presented the results of its Penetrium™ combinati...
2025-05-08 09:03
2708
SCG Announces Late-Breaking Clinical Data of SCG101 in HBV-Related Hepatocellular Carcinoma Presented at EASL 2025
SINGAPORE, May 8, 2025 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, today announced late-breaking clinical data from its Phase 1 trial evaluating SCG101, autologous HBV-specific...
2025-05-08 09:00
2455
Brii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179's Role in Advancing Higher HBsAg Loss
* End of treatment (EOT) data from Cohort 4 of the ENSURE study suggest that patients responding to prior BRII-179 treatment achieved faster and higher rate of surface antigen clearance with curative treatments compared to BRII-179naïve participants, strengthening the case for a novel enrichmen...
2025-05-08 08:10
2765
Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy
MELBOURNE, Australia and INDIANAPOLIS, May 8, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its Fibroblast Activation Protein (FAP)-targeting therapy candidate, TLX400, has been published inThyroid, the official journal of the ...
2025-05-08 05:00
2333
Hanx Biopharmaceuticals, Ltd. Showcases Five Innovative Cancer Therapies at 2025 AACR Annual Meeting
CHICAGO, May 7, 2025 /PRNewswire/ -- Hanx Biopharmaceuticals Ltd. (HanxBio), a clinical-stage biotechnology company pioneering next-generation immunotherapies, highlighted its expanding oncology and autoimmune disease pipeline with five research poster presentations at the 2025 American Associat...
2025-05-07 21:30
2022
Lunit to Power Germany's Largest Private Radiology Network with AI Imaging
The five-year framework agreement covers phased rollout of Lunit's AI suite—including chest X-ray, mammography, tomosynthesis, and fracture detection—across 79 Starvision sites SEOUL, South Korea, May 7, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics ...
2025-05-07 21:00
2578
Minaris Advanced Therapies launches as the leading global partner dedicated to cell therapy development, manufacturing, and testing
New company unveiled at the annual ISCT conference in New Orleans combines two tenured and innovative CDMOs with a testing powerhouse PHILADELPHIA, May 7, 2025 /PRNewswire/ -- Through strategic acquisitions made by New York–based investment firm Altaris, Minaris Regenerative Medicine and the U.S...
2025-05-07 20:12
2280
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids
* Primary Endpoint Met: Statistically significant reduction in heavy menstrual bleeding achieved in all dosage of Merigolix groups compared to placebo * Broader Therapeutic Potential: Positive Phase 2 results in both uterine fibroids and endometriosis could place Merigolix as a strong best-in...
2025-05-07 20:00
2305
The world's first: Grand Pharma's global innovative product STC3141 successfully reached the clinical endpoint in the Phase II clinical study in China
* The results showed that the SOFA scores of the drug treatment groups on the 7th day were significantly lower than those of the baseline, especially in the high-dose group, where the decrease was significantly greater than that in the placebo group, of which the difference was statistically si...
2025-05-07 14:19
3766
Britishpedia Honours Family Podiatry Centre Founder, Mark Reyneker, As a Success Icon
SINGAPORE, May 7, 2025 /PRNewswire/ -- Mark Reyneker, founder of the Family Podiatry Centre, will be featured in the 7th Edition of Britishpedia's "Successful People in Malaysia and Singapore." He has been recognised for his significant contributions to podiatry in Singapore and Malaysia, highlig...
2025-05-07 10:00
1729
Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc.
* AJICAP® Antibody-Drug Conjugate Manufacturing Technology Contributes to Enhanced Efficacy of Antibody Drugs TOKYO, May 7, 2025 /PRNewswire/ -- Ajinomoto Co., Inc. (President: Shigeo Nakamura, Headquarters: Chuo-ku, Tokyo, hereinafter referred to as "Ajinomoto") has been conducting joint resea...
2025-05-07 08:03
2060
Bispecific vs. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study of Efdamrofusp Alfa (IBI302), a First-in-class Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Diabetic Macular Edema
SAN FRANCISCO and SUZHOU, China, May 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ...
2025-05-07 08:00
3743
CStone Presents Preclinical Results of CS2011 (EGFR/HER3 bispecific antibody), CS5007 (EGFR/HER3 bispecific ADC), CS5005 (SSTR2 ADC) and CS5006 (ITGB4 ADC) at 2025 AACR
SUZHOU, China, May 6, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on anti-cancer therapies, announced today that poster presentations of preclinical data of CS2011 (EGFR/HER3 bispecific antibody), CS5007 (EGFR/HER3 bis...
2025-05-07 08:00
2043
Everest Medicines Announces NMPA Full Approval of NEFECON® for the Treatment of Primary Immunoglobulin A nephropathy (IgAN) in Adults at Risk of Disease Progression
SHANGHAI, May 7, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the supplemental New Drug Applica...
2025-05-07 07:30
2592
Formosa Pharmaceuticals Announces Licensing Agreement with Apotex Inc., for Commercialization of Clobetasol Propionate Ophthalmic Suspension for Post-Ocular Surgery Inflammation and Pain for Mexico
TAIPEI, May 6, 2025 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals (" Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Apotex Inc. ("Apotex"), for exclusive rights inMexico for the commercialization of clobetasol propionate ophthalmic...
2025-05-07 06:30
2544
FutureLink Boston 2025 Reinforces TraceLink's Leadership in Supply Chain Orchestration and Innovation
BOSTON, May 7, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent supply chain orchestration, successfully hosted FutureLink Boston 2025, bringing together more than 150 attendees ranging across senior executives, industry experts, and supply chain tech...
2025-05-07 00:39
2266
Plasmidsaurus Opens 10th Global Lab in Singapore, Scaling to Meet the Demand for Cutting-Edge Sequencing Around the World
SINGAPORE and SOUTH SAN FRANCISCO, Calif., May 6, 2025 /PRNewswire/ -- Plasmidsaurus, the company that sequences while you sleep, today announced the opening of its tenth global sequencing lab, located inSingapore's vibrant biomedical hub. The new site dramatically shortens turnaround times for ...
2025-05-06 23:56
2582
Paradigm Therapeutics, Inc. Announces Investment by Eshelman Ventures, LLC to Support Completion of Development of SD-101 (Zorblisa™), A Topical Therapy for Treatment Across the Entire Skin Surface of All Subtypes of Epidermolysis Bullosa (EB)
First Topical Therapy Developed to Treat the Wounds and Lesions on the Entire Skin Surface Across All EB Subtypes Funding to be Used for Completion of All Activities to Support Planned NDA Submission in the Second Half of 2025, Along with Plans for Commercialization in the U.S. MT PLEASANT, S...
2025-05-06 22:12
2908
Formosa Pharmaceuticals and Almac Discovery Announce Licensing Agreement for ALM-401, a First-in-Class Bispecific ADC targeting EGFR/ROR1 for the Treatment of Solid Tumors
TAIPEI, May 6, 2025 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced that the company has entered into an exclusive licensing agreement with Almac Discovery, aNorthern Ireland-based research driven drug discovery company, for exclusive rights to the commercializ...
2025-05-06 21:00
2581
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 315 media titles]
2026-01-23 11:03
UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 305 media titles]
2026-01-23 09:00AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 302 media titles]
2026-01-21 12:39Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 297 media titles]
2026-01-22 15:16
Klook's study of 374,000 reviews finds that lesser-known cities create deeper emotional connection with travelers
[Picked up by 280 media titles]
2026-01-20 15:40
Most Read
GIGABYTE Strengthens NVIDIA® Partnership to Drive Innovation in AI-Powered Gaming and Creative Solutions
2026-01-17 00:00
7453
